BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
about
Evaluation of Bioequivalence of Two Long-Acting 20% Oxytetracycline Formulations in PigsOptimization of Dissolution Compartments in a Biorelevant Dissolution Apparatus Golem v2, Supported by Multivariate Analysis.Evaluation of Marbofloxacin in Beagle Dogs After Oral Dosing: Preclinical Safety Evaluation and Comparative Pharmacokinetics of Two Different Tablets.Regulatory requirements for the registration of generic medicines and format of drug dossiers: procedures in Sri Lanka in comparison with selected regulatory authorities.Association of Variability and Pharmacogenomics With Bioequivalence of Gefitinib in Healthy Male Subjects
P2860
BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
@en
BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
@nl
type
label
BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
@en
BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
@nl
prefLabel
BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
@en
BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
@nl
P2093
P2860
P1433
P1476
BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements
@en
P2093
Isadore Kanfer
Jean-Michel Cardot
Yu Chung Tsang
P2860
P2888
P304
P356
10.1208/S12248-016-9877-2
P407
P577
2016-03-04T00:00:00Z
P6179
1016812032